Linda S. Barton

Direct design of a potent non-peptide fibrinogen receptor antagonist based on the structure and conformation of a highly constrained cyclic RGD peptide

Thomas W. Ku, Fadia E. Ali, Linda S. Barton et al. · Journal of the American Chemical Society · 1993 · 90 citations

Peptide Engineering, Altmetric Attention Score, Peptide Science +22

Potent, Selective, Orally Active 3-Oxo-1,4-benzodiazepine GPIIb/IIIa Integrin Antagonists

James M. Samanen, Fadia E. Ali, Linda S. Barton et al. · Journal of Medicinal Chemistry · 1996 · 72 citations · Full text

Altmetric Attention Score, Pharmacotherapy, Experimental Pharmacology +17

The discovery of potent blockers of the canonical transient receptor channels, TRPC3 and TRPC6, based on an anilino-thiazole pharmacophore

David G. Washburn, Dennis A. Holt, Jason W. Dodson et al. · Bioorganic & Medicinal Chemistry Letters · 2013 · 58 citations · Full text

Signal Transduction, Biochemistry, Anilino-thiazole Pharmacophore +9

Discovery of GSK2798745: A Clinical Candidate for Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4)

Carl Brooks, Linda S. Barton, David J. Behm et al. · ACS Medicinal Chemistry Letters · 2019 · 51 citations · Full text

Orally bioavailable nonpeptide vitronectin receptor antagonists containing 2-aminopyridine arginine mimetics

Richard M. Keenan, William H. Miller, Linda S. Barton et al. · Bioorganic & Medicinal Chemistry Letters · 1999 · 30 citations · Full text

Pharmacology, Pharmacological Agent, Pharmacotherapy +5